Nutritional and Pharmaceutical Aspects of Calcium Supplementation

Carr, C. Jelleff; Shangraw, Ralph F.

doi:10.1016/s0160-3450(15)32077-8

Cited by 57 publications

(22 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Calcium carbonate disintegration and dissolution are pH-dependent and impaired by alkaline environments, decreasing from 96% at pH 1 to 23% at pH 6.1 [48]. Animal studies have shown that gastrectomy or PPI use and the resulting alkalization of the gastric environment may impair calcium absorption and bone density [49,50].…”

Section: Risk Of Fracturesmentioning

confidence: 99%

Adverse Effects of Long-Term Proton Pump Inhibitor Therapy

2011

View full text Add to dashboard Cite

Proton pump inhibitors have an excellent safety profile and have become one of the most commonly prescribed class of drugs in primary and specialty care. Long-term, sometimes lifetime, use is becoming increasingly common, often without appropriate indications. This paper is a detailed review of the current evidence on this important topic, focusing on the potential adverse effects of long-term proton pump inhibitor use that have generated the greatest concern: B12 deficiency; iron deficiency; hypomagnesemia; increased susceptibility to pneumonia, enteric infections, and fractures; hypergastrinemia and cancer; drug interactions; and birth defects. We explain the pathophysiological mechanisms that may underlie each of these relationships, review the existing evidence, and discuss implications for clinical management. The benefits of proton pump inhibitor use outweigh its risks in most patients. Elderly, malnourished, immune-compromised, chronically ill, and osteoporotic patients theoretically could be at increased risk from long-term therapy.

show abstract

Section: Risk Of Fracturesmentioning

confidence: 99%

Adverse Effects of Long-Term Proton Pump Inhibitor Therapy

2011

View full text Add to dashboard Cite

show abstract

“…This effect is contradicted by Carr and Shangraw they reported that daily omeprazole increased the median stomach pH and that the corrected calcemia was significantly lower under omeprazole [26].…”

mentioning

confidence: 85%

Comparative Study Between the Effect of Histamine Receptor Antagonists of Type Ii (Famotidine) and Proton Pump Inhibitors (Omeprazole) on the Efficacy of Calcium Carbonate as Phosphate Binder in Haemodialysis Patient

Aboelyazeed

El-Haggar

Okasha

2017

Int J Pharm Pharm Sci

View full text Add to dashboard Cite

Objective: The purpose of this study was to compare the effect of famotidine versus omeprazole on the efficacy of calcium carbonate as a phosphate binder in the hemodialysis patient. mo with significant decreased (p<0.05) in serum calcium comparing with pre-treatment. Group III showed no significant change (p>0.05) in serum calcium, phosphorus and parathyroid hormone (PTH) comparing with pre-treatment. Both groups (II and III) showed a significant decrease in alkaline phosphatase (ALP) (p<0.05).

show abstract

“…L'hypothèse physiopathologique avancée pour expliquer une augmentation de l'incidence des fractures sous un traitement par IPP au long cours repose sur une malabsorption intestinale du calcium : en effet, l'augmentation du pH gastro-intestinal induite par les IPP empêcherait l'ionisation du calcium à partir des sels de calcium insolubles ingérés [8], étape fondamentale pour l'absorption du calcium [9]. Plusieurs auteurs en ont déduit que ces fractures relevaient d'un mécanisme ostéoporotique [4,5].…”

Section: Risque Fracturaireunclassified

Effets indésirables des inhibiteurs de la pompe à proton : faut-il craindre de les prescrire au long cours ?

Roulet

Vernaz

Giostra

et al. 2012

La Revue de Médecine Interne

View full text Add to dashboard Cite

Mots clés :Inhibiteurs de la pompe à proton Fractures ostéoporotiques Infections Cancer gastrique Pharmacodépendance r é s u m é La prévalence des traitements de longue durée par inhibiteurs de la pompe à proton (IPP) est en augmentation. Si leur tolérance à court terme est bonne, des réserves ont vu le jour sur d'éventuels effets indésirables graves associés à une exposition prolongée. Ainsi, l'association avec le risque fracturaire semble être confirmée, notamment au niveau vertébral, ainsi que le risque d'effet rebond sur la sécrétion acide à l'arrêt du traitement. Le risque de pneumopathie communautaire n'est pas établi dans la population générale et semble limité aux patients les plus fragiles. L'association avec le risque d'infection digestive à Clostridium difficile est probable. Les cas de néphrite tubulo-intestitielle sont rares mais peuvent conduire à une insuffisance rénale chronique. Les données disponibles sont encore insuffisantes pour évaluer le risque de carence en vitamine B12, en fer ou en magnésium et le risque de cancer digestif, même si des bases physiopathologiques existent dans le cas du cancer gastrique. Il existe des interactions avec de nombreux autres médicaments, notamment ceux qui sont métabolisés par certaines isoenzymes du cytochrome P450. Enfin, la balance bénéfice-risque de l'utilisation des IPP au long cours chez l'enfant semble défavorable dans la plupart des cas.© 2012 Société nationale française de médecine interne (SNFMI). Publié par Elsevier Masson SAS. Tous droits réservés. Keywords: Proton pump inhibitors Osteoporotic fractures Infection Stomach neoplasms Substance withdrawal syndrome a b s t r a c tLong-term treatment with proton pump inhibitors (PPI) is becoming more prevalent. Although they are well tolerated in the short term, serious concerns about long-term use have arisen. Recent data suggest that the latter is associated with an increased risk for osteoporotic fracture (especially vertebral), Clostridium difficile infection and rebound acid hypersecretion after treatment discontinuation. Acute interstitial nephritis is rare but may progress to chronic renal failure. An increased risk of communityacquired pneumonia has not been established in the general population and seems limited to the most vulnerable patients. Consistent data are still missing to correctly assess the risk of iron deficiency, vitamin B12 deficiency or hypomagnesaemia and the risk of digestive malignant diseases, despite the pathophysiological basis that exists concerning gastric malignancy. Many drug interactions can occur on long-term treatment, including some that imply the cytochrome P450 enzymes. Finally, the risk-benefit balance for a chronic PPI use in children seems unfavorable in most cases.

show abstract

Nutritional and Pharmaceutical Aspects of Calcium Supplementation

Cited by 57 publications

References 20 publications

Adverse Effects of Long-Term Proton Pump Inhibitor Therapy

Adverse Effects of Long-Term Proton Pump Inhibitor Therapy

Comparative Study Between the Effect of Histamine Receptor Antagonists of Type Ii (Famotidine) and Proton Pump Inhibitors (Omeprazole) on the Efficacy of Calcium Carbonate as Phosphate Binder in Haemodialysis Patient

Effets indésirables des inhibiteurs de la pompe à proton : faut-il craindre de les prescrire au long cours ?

Contact Info

Product

Resources

About